pipette
ESEspañol

Chimeric antigen receptor T cell therapy targeting CD94 for cytotoxic T/NK cell malignancies

C. C. Le, J. Weng, J. Liu, F. M. Aletti, X. Cherng, Y. Tang, S. Patchva, M. Richard, M. Balakumaran, M. M. Piubelli, L. M. Solis Soto, W. Lu, C.-Y. Lin, F. Chu, J. Cao, A. Rehman, K. Singh, O. Agbedia, S. Gouni, K. Chohan, F. Darbaniyan, S. Kolsuz, K. Balakrishnan, N. Saini, M. R. Green, C. R. Flowers, S. Iyer, F. Vega, S. S. Neelapu

PreprintReal-world use

In the authors' words

Chimeric antigen receptor (CAR) T cell therapy against pan-B-cell antigens is highly effective, but analogous approaches for T-cell lymphomas risk prolonged T-cell aplasia. We developed a CAR-T therapy targeting a post-thymic antigen, CD94, a receptor with restricted expression in normal tissues and immune cells but enriched in cytotoxic T/NK-cell malignancies. Second generation CD94 CAR T cells generated using a specific and high-affinity anti-CD94 monoclonal antibody showed potent and selective cytotoxicity against CD94-positive tumor cells in vitro and completely eradicated NK-cell leukemia xenografts and patient-derived xenograft models of hepatosplenic T-cell lymphoma and NK/T-cell lymphoma in vivo. Incorporation of truncated B-cell maturation antigen (BCMA) as a safety switch enabled rapid elimination of CAR T cells using anti-BCMA T-cell engagers or anti-BCMA antibody-drug conjugate. Super-resolution microscopy demonstrated intracellular sequestration of CD94 by the CAR, preventing fratricide. Collectively, these findings support anti-CD94 CAR-T therapy as a promising and novel treatment for cytotoxic T/NK-cell neoplasms.

Main resultThe abstract does not state a limitation.

Appeared: Tuesday, November 17. bioRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.12.765663